Chronic kidney disease (CKD) refers to a set of heterogenous disorders that affect the structure and function of the kidneys. The CKD drug market comprises a wide variety of antihypertensive…
Immune checkpoint inhibitors have greatly altered the treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC). Initially confined to treatment of advanced disease, the…
Retinal vein occlusion (RVO) is a major cause of blindness in the major pharmaceutical markets. Patients are segmented by the anatomic location of the occlusion; thus, they are classified as having…
Hormonal therapy is the cornerstone of drug treatment for prostate cancer in all patient populations. Abiraterone and Xtandi (Pfizer / Astellas Pharma) dominate the metastatic castrate-resistant…
Hormonal therapy is the cornerstone of drug treatment for prostate cancer in all patient populations. Abiraterone and Xtandi (Pfizer / Astellas Pharma) dominate the metastatic castrate-resistant…
Sickle cell disease (SCD) is a rare genetic blood disorder characterized by polymerization of hemoglobin in red blood cells that distorts them into a sickle shape. This sickling leads to various…
Sickle cell disease (SCD) is a rare genetic blood disorder characterized by polymerization of hemoglobin in red blood cells that distorts them into a sickle shape. This sickling leads to various…
Multiple myeloma is a hematologic malignancy that arises from an overproduction of plasma cells in the bone marrow. In patients with active disease, immunomodulatory drugs (e.g., Revlimid, Pomalyst…
Multiple myeloma is a hematologic malignancy that arises from an overproduction of plasma cells in the bone marrow. In patients with active disease, immunomodulatory drugs (e.g., Revlimid, Pomalyst…
The wet age-related macular degeneration (AMD) therapy market has long been dominated by three vascular endothelial growth factor (VEGF) inhibitors: Roche / Genentech / Chugai’s Avastin, Roche /…
The market for nonalcoholic steatohepatitis (NASH), a severe form of nonalcoholic fatty liver disease (NAFLD), offers substantial commercial opportunity for drug developers owing to the lack of…
The treatment of Parkinson’s disease (PD) requires personalized care, a high degree of polypharmacy, and frequent adjustments to achieve symptom control throughout the disease course…
The treatment of Parkinson’s disease (PD) requires personalized care, a high degree of polypharmacy, and frequent adjustments to achieve symptom control throughout the disease course…
Migraine, which afflicts approximately 72 million people in the major pharmaceutical markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment…
The treatment landscape for atopic dermatitis (AD) in the United States is undergoing a revolution. Since 2017, six agents have been approved by the FDA (four of these since the start of 2021),…